CYT997: Additional Phase I data

Additional data from the open-label, dose-escalation, Australian Phase I QP04C07 trial in 31 patients showed that 24-hour IV infusions of CYT997 every 3 weeks were well tolerated up to 202 mg/m 2. Rev...